275 related articles for article (PubMed ID: 29436940)
1. Biomarker threshold adaptive designs for survival endpoints.
Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
[TBL] [Abstract][Full Text] [Related]
2. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
[TBL] [Abstract][Full Text] [Related]
3. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
Wang X; Zhou J; Wang T; George SL
J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
[TBL] [Abstract][Full Text] [Related]
4. Quantifying treatment effects using the personalized chance of longer survival.
Zhao YQ; Redman MW; LeBlanc ML
Stat Med; 2019 Dec; 38(28):5317-5331. PubMed ID: 31502297
[TBL] [Abstract][Full Text] [Related]
5. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
6. Strategies for power calculations in predictive biomarker studies in survival data.
Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
[TBL] [Abstract][Full Text] [Related]
7. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
Li W; Chen C; Li X; Beckman RA
Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
[TBL] [Abstract][Full Text] [Related]
8. Inference for multimarker adaptive enrichment trials.
Simon R; Simon N
Stat Med; 2017 Nov; 36(26):4083-4093. PubMed ID: 28795420
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.
Herrera Gómez RG; Saleh K; Mayache L; Iacob M; Baste N; Even C
Oral Oncol; 2021 Jan; 112():104984. PubMed ID: 32888816
[No Abstract] [Full Text] [Related]
10. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
11. New designs for basket clinical trials in oncology.
Simon R
J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
[TBL] [Abstract][Full Text] [Related]
12. A response adaptive design for ordinal categorical responses.
Biswas A; Bhattacharya R; Das S
J Biopharm Stat; 2018; 28(6):1169-1181. PubMed ID: 29504826
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
[TBL] [Abstract][Full Text] [Related]
14. Optimal response-adaptive randomized designs for multi-armed survival trials.
Sverdlov O; Tymofyeyev Y; Wong WK
Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
[TBL] [Abstract][Full Text] [Related]
15. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
[TBL] [Abstract][Full Text] [Related]
16. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
17. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Weinberg BA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
[No Abstract] [Full Text] [Related]
19. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
20. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
